Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 4, 2011, Pages 254-259

  Kostovski, Emil ^a   Dahm, Anders E A ^b   Iversen, Nina ^c   Hjeltnes, Nils ^a   Østerud, Bjarne ^d   Sandset, Per Morten ^b,e   Iversen, Per O ^b,f  

^a SUNNAAS REHABILITATION HOSPITAL   (Norway)

^b Department of Haematology ^*  (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e Institute of Clinical Medicine   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

Author keywords

circadian rhythm; endothelium; melatonin; tissue factor pathway inhibitor

Indexed keywords

MELATONIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CELL CULTURE; DOSE RESPONSE; DRUG ACTIVITY; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM;

CELL CULTURE TECHNIQUES; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR SPACE; HUMANS; LIPOPROTEINS; MELATONIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; THROMBOPLASTIN; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 79955943668     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283442ce2     Document Type: Article

References (24)

1. Bilora F, Manfredini R, Petrobelli F, Vettore G, Boccioletti V, Pomerri F. Chronobiology of non fatal pulmonary thromboembolism. Panminerva Med 2001; 43:7-10. (Pubitemid 33636909)
2. Iversen PO, Dahm A, Sandset PM. Circadian variations within the hemostatic and fibrinolytic systems with emphasis on venous thromboembolism. In: Columbus F, editor. Chronobiology research progress. New York: Nova; 2006. pp. 113-129.
3. Johe PD, Osterud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. J Pineal Res 2005; 39:324-330. (Pubitemid 41337815)
4. Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1?2, and plasmin- plasmin inhibitor complex. Circulation 1997; 96:19-21. (Pubitemid 27298396)
5. Undar L, Ertugrul C, Altunbas H, Akca S. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 1999; 81:571-575. (Pubitemid 29178943)
6. Iversen PO, Groot PD, Hjeltnes N, Andersen TO, Mowinckel MC, Sandset PM. Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. Br J Haematol 2002; 119:1011-1016. (Pubitemid 35463827)
7. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:16-19.
8. Chowdhury I, Sengupta A, Maitra SK. Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human. Indian J Biochem Biophys 2008; 45:289-304.
9. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336:186-195. (Pubitemid 27034965)
10. DahmA, Osterud B, Hjeltnes N, Sandset PM,Iversen PO.Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation? J Thromb Haemost 2006; 4:1840-1842. (Pubitemid 44144817)
11. Kneisley LW, Moskowitz MA, Lynch HG. Cervical spinal cord lesions disrupt the rhythm in human melatonin excretion. J Neural Transm Suppl 1978; 13:311-323.
12. Sandset PM, Abildgaard U. Tissue factor pathway inhibitor (TFPI): an update. Haemostasis 1996; 26:154-165. (Pubitemid 26417433)
13. Johannsson E, Henriksen T, Iversen PO. Increase in matrix metalloproteinases from endothelial cells exposed to umbilical cord plasma from high birth weight newborns. Am J Physiol Regul Integr Comp Physiol 2007; 292:1563-1568.
14. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-2756.
15. Whatley RE, Satoh K, Zimmerman GA, McIntyre TM, Prescott SM. Proliferation-dependent changes in release of arachidonic acid from endothelial cells. J Clin Invest 1994; 94:1889-1900. (Pubitemid 24348226)
16. Iversen PO, To LB, Lopez AF. Apoptosis of hemopoietic cells by the human granulocyte-macrophage colony-stimulating factor mutant E21R. Proc Natl Acad Sci U S A 1996; 93:2785-2789.
17. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101:4387-4392. (Pubitemid 36857803)
18. Rocha SF, Adams RH. Molecular differentiation and specialization of vascular beds. Angiogenesis 2009; 12:139-147.
19. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006; 54:385-395.
20. Fjaerli O, Lund T, Osterud B. The effect of melatonin on cellular activation processes in human blood. J Pineal Res 1999; 26:50-55. (Pubitemid 29113051)
21. Aoki T, Nomura R, Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 1999; 253:629-636. (Pubitemid 30003124)
22. Pinotti M, Bertolucci C, Portaluppi F, Colognesi I, Frigato E, Foà A, Bernardi F. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005; 25:646-649. (Pubitemid 40315692)
23. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J Pineal Res 2001; 31:281-288. (Pubitemid 32905239)
24. Pogan L, Bissonnette P, Parent L, Sauve R. The effects of melatonin on Ca(2) homeostasis in endothelial cells. J Pineal Res 2002; 33:37-47. (Pubitemid 34833073)